Slowing or Delaying Vision Loss in Retinitis Pigmentosa (USH2A gene mutation subtype) → Gene Therapy Can Slow or Stop Progression → Contribution
Can antisense oligonucleotide therapy help USH2A RP?
Method
Review of early-stage clinical trials and publications on AON therapies targeting USH2A mutations.
Data / Sources
Published clinical trial data, PubMed literature on exon-skipping approaches for USH2A.
Result
Some AON therapies (e.g., exon skipping approaches) show potential in targeting specific USH2A mutations. ProQR's ultevursen (QR-421a) has advanced to Phase 2/3 trials.
Insight
Mutation-specific therapies may be promising but not universally applicable. Different USH2A mutations may require different AON designs.
Suggested Next Step
Track ProQR trial results. Identify which specific mutations are targetable by current AON approaches.